USPTO serial 76471856
PROBIODRUG
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Apr 20, 2004
- Examiner
- SMITH, BRIDGETT G
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with PROBIODRUG?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
06120 Halle, DE
06120 Halle, DE
06120 Halle, DE
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
David Toren
KATRIN LEWERTOFF SIDLEY AUSTIN LLP787 7TH AVENEW YORK, NY 10019UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical preparations for the use in the manufacture of pharmaceuticals for the treatment of type 2 diabetes, impaired glucose tolerance, glucosuria, and disturbances of signal action at the cells of the islets of Langerhans and insulin sensitivity in the peripheral tissue in the postprandial phase of mammals, insulin resistance, metabolic acidosis, diabetic neuropathy and nephropathy and of sequelae caused by diabetes mellitus, diabetes mellitus type 1, lipid disorders, hyperlipidemia, metabolism-related hypertension and cardiovascular sequelae caused by hypertension in mammals, atherosclerosis and its sequelae, inflammatory bowel disease, namely, Crohn's disease and ulcerative colitis, pancreatitis, tumor metastasis, benign prostatic hypertrophy, gingivitis, osteoporosis, for the prophylaxis or treatment of skin diseases and diseases of the mucosae, autoimmune diseases and inflammatory conditions, and for the prophylaxis or treatment of psychosomatic, neuropsychiatric and depressive illness, and neurodegenerative diseases namely anxiety, depression, sleep disorders, chronic fatigue, schizophrenia, epilepsy, nutritional disorders, spasm, and chronic pain, multiple sclerosis, Alzheimer's disease, Down Syndrome, and for use in the manufacture of contraceptive drugs for scientific, medical and biological purposes, diagnostic preparations and reagents for use in scientific and medical research | SECTION 8 - CANCELLED | — |
| 005 | Pharmaceutical preparations for the treatment of non-insulin dependent diabetes mellitus (type 2), impaired glucose tolerance, glucosuria, and disturbances of signal action at the cells of the islets of Langerhans and insulin sensitivity in the peripheral tissue in the postprandial phase of mammals, insulin resistance, metabolic acidosis, diabetic neuropathy and nephropathy and of sequelae caused by diabetes mellitus, diabetes mellitus type 1, lipid disorders, hyperlipidemia, metabolism-related hypertension and cardiovascular sequelae caused by hypertension in mammals; pharmaceutical preparations for the treatment of atherosclerosis and its sequelae, inflammatory bowel disease, namely, Crohn's disease and ulcerative colitis, pancreatitis, tumor metastasis, benign prostatic hypertrophy, gingivitis, osteoporosis; pharmaceutical preparations for the prophylaxis or treatment of skin diseases and diseases of the mucosae, autoimmune diseases and inflammatory conditions, and for the prophylaxis or treatment of psychosomatic, neuropsychiatric and depressive illness, and neurodegenerative diseases namely, anxiety, depression, sleep disorders, chronic fatigue, schizophrenia, epilepsy, nutritional disorders, spasm, and chronic pain, multiple sclerosis, Alzheimer's disease; Veterinary preparations for the treatment of metabolic diseases, cancerous diseases, psychosomatic, neuropsychiatric, depressive and neurodegenerative diseases in livestock and domestic animals; All purpose disinfectants, diagnostic reagents for clinical or medical use; Dietary supplements, food for enteral feeding; Agrochemicals, namely fungicides, herbicides and insecticides for agricultural and domestic use | SECTION 8 - CANCELLED | — |
| 010 | surgical, medical, dental and veterinary instruments and apparatus, namely electronic monitors, recorders and analyzers for blood pressure, blood analysis, blood glucose, insulin in the blood, pH Monitors | SECTION 8 - CANCELLED | — |
| 041 | educational services, namely conducting classes, seminars, conferences and workshops in the field of human medicine, veterinary medicine, human nutrition, pet nutrition and agriculture | SECTION 8 - CANCELLED | — |
| 042 | Chemist, physicist, microbiologist, biologist and Chemical, biological and medical research in the field of drugs and genetic engineering | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Probiodrug AG
- Other trademarks owned by Probiodrug AG
- Other trademarks owned by Probiodrug AG
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 041
- Other trademarks in Class 042
- Similar marks named PROBIODRUG
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 26, 2010 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Jul 6, 2006 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 20, 2004 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 27, 2004 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 7, 2004 | NPUB | NOTICE OF PUBLICATION | — |
| Nov 25, 2003 | 1.BD | Sec. 1(B) CLAIM DELETED | — |
| Nov 14, 2003 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 13, 2003 | PAPER RECEIVED | — | |
| Oct 27, 2003 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 23, 2003 | CNEA | EXAMINERS AMENDMENT MAILED | — |
| Jul 2, 2003 | CFIT | CASE FILE IN TICRS | — |
| Jun 16, 2003 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 16, 2003 | PAPER RECEIVED | — | |
| Mar 24, 2003 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 12, 2003 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 31, 2003 | PAPER RECEIVED | — |